Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China  by Li, Ziming et al.
ORIGINAL ARTICLE
Analysis of the T Descriptors and Other Prognosis Factors
in Pathologic Stage I Non-small Cell Lung Cancer in China
Ziming Li, MD,* Yongfeng Yu, MD,* Jiade Lu, MD, MBA,‡ Qinquan Luo, MD,* Chunxiao Wu, MD,†
Meilin Liao, MD,* Ying Zheng, PhD,† Xinghao Ai, MD,* Lingping Gu, MD,* and
Shun Lu, MD, PhD*
Background: The seventh edition of the tumor, node, metastasis
Classification of Malignant Tumors is due to be published in 2009. The
recommendations of International Association for the Study of Lung
Cancer for changes to the T descriptors have been published. We
combined this new parameter with other well-established prognostic
factors and performed multivariate survival analyses to validate its
value in Chinese stage I non-small cell lung cancer (NSCLC).
Methods: We try to validate the new staging project in 325 patients
who underwent complete surgical resection for stage I NSCLC in
Single Institution of Shanghai Chest Hospital from 1998 to 2003.
Variables in the analysis included age, gender, performance status,
history of smoking, pathologic type, type of resection (pneumonec-
tomy, lobectomy, and bilobectomy), tumor size (greatest dimension of
tumor), T-status (T1 or T2), type of lymph node resection (systematic
mediastinal lymphadenectomy or mediastinal lymph node sampling),
lymphovascular vessel invasion, and adjuvant chemotherapy.
Results: The 5-year overall survival (OS) of patients whose tumor
measured no larger than 2 cm in largest diameter or larger than 2 cm
but no larger than 3 cm were 75.49 and 74.58%, respectively. For
those with tumors measured larger than 3 cm but smaller than 5 cm
or larger than 5 cm but smaller than 7 cm were 60.87 and 55.63%.
The 5-year OS of patients whose tumor measured larger than 7 cm
was 46.15% (p  0.025). The 5-year disease-free survival rates of
patients whose tumor measured no larger than 2 cm in largest
diameter or larger than 2 cm but no larger than 3 cm were 67.65 and
66.67%, respectively. For those with tumors measured larger than 3
cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm
were 53.14 and 52.63%. The 5-year disease-free survival rate of
patients whose tumor measured larger than 7 cm was 30.77% (p 
0.009). Multivariate analyses revealed that age, gender, type of
resection (pneumonectomy, lobectomy, and bilobectomy), tumor
size (greatest dimension of tumor), type of lymph node resection
(systematic mediastinal lymphadenectomy or mediastinal lymph
node sampling), and lymphovascular vessel invasion were signifi-
cant predictive factors for OS.
Conclusions: The tumor size is a significant independent prognostic
factors in stage I NSCLC.
Key Words: Non-Small Cell Lung Cancer, TNM, Stage I, Progno-
sis factors.
(J Thorac Oncol. 2009;4: 702–709)
Surgical resection is the mainstay curative treatment modalityfor early-stage non-small cell lung cancer (NSCLC). How-
ever, the outcome of patients with stage I NSCLC after
complete surgical resection varies significantly, and the re-
ported 5-year overall survival (OS) ranged from 55 to
77.6%.1–3 The sixth edition of the Union Internationale Con-
tre le Cancer and the American Joint Committee on Cancer
tumor, node, metastasis (TNM) staging system has been used
for the staging of NSCLC since 2002. The variation after
definitive surgery for stage I NSCLC clearly indicated that
the current staging system is inadequate, at least for the
early-stage disease.
A new staging project was initiated by the International
Association for the Study of Lung Cancer (IASLC) in 1999,
with the goal of providing data for the next revision of the
international staging system.4–5 The committee provides an
analysis of the T-classification and suggested to subclassify
T1 as T1a and T1b (those 2 cm or smaller as T1a and those
larger than 2 cm but no larger than 3 cm as T1b), T2 as T2a
and T2b (those larger than 3 cm but no larger than 5 cm as
T2a and those larger than 5 cm but no larger than 7 cm as
T2b), reclassify T2 tumors larger than 7 cm as T3 in the next
Union Internationale Contre le Cancer/American Joint Com-
mittee on Cancer staging system for NSCLC.6
A total of 1732 NSCLC patients of various stages
treated with surgery from China were included in the IASLC
Lung Cancer Staging Project; however, the impact of the
suggested staging system on classifying Chinese patients with
NSCLC is unknown as subgroup analysis for different ethnic
groups were not performed by the IASLC project. The aim of
this study is to evaluate the value of the new classification as
well as other confirmed prognostic factors in predicting the
clinical behavior and outcome after definitive surgery of
pathologic stage I NSCLC in Chinese population.
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METHODS
Patients’ Characteristics and Diagnosis
Between July 1998 and June 2003, 423 patients were
diagnosed as clinical stage I NSCLC in Shanghai Chest
Hospital in this period. A total of 325 consecutive and
nonselected patients who underwent definitive surgery for
NSCLC at the Shanghai Chest Hospital with a confirmed
pathologic stage of stage I was reviewed retrospectively. All
patients had pathologically confirmed squamous cell carci-
noma, adenocarcinoma, adenosquamous cell carcinoma,
bronchioloalveolar carcinoma (BAC), or large cell carci-
noma. Small-cell lung cancer and cell types of undetermined
histology were excluded from this analysis.
Preoperative evaluation and staging work-ups included
a complete history and physical examination, bronchoscopy,
complete blood counts, serum biochemistry tests, computed
tomography of thorax, ultrasound of upper abdomen, brain
magnetic resonance imaging, total body bone scan, or FDG-
positron emission tomography scan. There are 31 patients
who received fluorodeoxyglucose-positron emission tomog-
raphy scan.
Treatment
All patients underwent lobectomy, bilobectomy, or
pneumonectomy, and achieved a complete tumor resection
with microscopically tumor-free margin (R0). The extension
of pulmonary resection and mediastinal lymph node removal
were decided at the time of operation by operating surgeons
and the general physical condition of the patients. Systematic
mediastinal lymphadenectomy is described by Martini.7 Briefly,
in right-sided tumors, the superior mediastinal compartment
contained between the trachea, the superior vena cava from the
level of the azygos vein to the right subclavian artery, and the
right recurrent laryngeal nerve was dissected and the trachea,
azygos vein, superior vena cava, and ascending aorta were
completely freed from all tissue. The azygos vein and the
vagus nerve were generally spared, and the right laryngeal
nerve was exposed. The anterior mediastinum anteriorly to
the superior vena cava was also routinely removed, including
the associated thymic tissue. Subcarinal, paraesophageal, and
inferior pulmonary lymph nodes were removed en bloc. In
left-sided cancer, the subaortic compartment contained be-
tween the left pulmonary artery, the aortic arch, the left
recurrent laryngeal nerve, and the phrenic nerve was dis-
sected by completely freeing the left vagal nerve and the
recurrent laryngeal nerve.
In patients received mediastinal lymph node sampling,
the resection was combined with a regional lymph node
dissection of interlobular, peribronchial, and hilar nodes rep-
resenting nodes 10, 11, and 12 according to the lymph node
mapping proposed by Naruke et al.8 A mediastinotomy was
performed through longitudinal incision of the mediastinal
pleura, and nodes of regions two to nine were explored. Any
nodes showing evidence of cancer were removed and sub-
mitted for pathohistologic analysis. For right-sided tumors,
nodes of regions three, four, and seven, and for left-sided
tumors, nodes of regions five, six, and seven were removed
routinely in all patients.
We defined the degrees of visceral pleural involve-
ment (VPI) as follows according to Hammar’s9 staging
classification: p0, tumor that does not penetrate the elastic
layer of the visceral pleura; p1, tumor that penetrates the
elastic layer but is not exposed on the pleural surface; and
p2, tumor that is exposed on the pleural surface but does
not involve the parietal pleura. All slides were checked by
two pathology doctors.
As the role of adjuvant chemotherapy for NSCLC was
controversial at the time of the treatment of this group of
patients, the utilization of chemotherapy was not standard-
ized. The adjuvant chemotherapy was decided by doctors and
the general physical condition of the patients. Adjuvant radiation
therapy was not used in this group of patients.
Statistical Analysis
The duration of OS was calculated from diagnosis until
death or until the date of the last follow-up visit for patients
still alive. Disease-free survival (DFS) was measured from
the completion of the treatment until documented treatment
failure. Survival probabilities were calculated by Kaplan-
Meier method. Variables included in the analyses of progno-
sis included age, gender, Eastern Cooperative Oncology
Group performance scale, history of smoking, histopatholog-
ical diagnosis, presence of lymphvascular invasion on patho-
logic specimen, type of lymph node removal (systematic
nodal dissection or mediastinal lymph node sampling), type
of surgical resection (pneumonectomy, lobectomy, and bilo-
bectomy), as well as the extent of disease including the
greatest dimension of tumor and the T-category. The log-rank
test was used in univariate survival analysis to compare
different survival probabilities among different levels within
each categorical variable (prognostic factor). The p value was
set at 0.05 in advance for each univariate analysis. It de-
pended on clinical experience and statistical analysis to de-
cide whether continuous variables should be categorized.
Possible prognostic factors associated with survival probabil-
ity at a significance level of 0.20 or less were considered in a
multivariable Cox’s proportional hazard regression analysis.
RESULTS
A total of 325 patients were included in this study. The
median age of all patients was 65 (range 33–80). Surgical
procedures included pneumonectomies in six patients, bilo-
bectomies in 19 patients, and lobectomies in 300 patients.
Two hundred twenty-nine patients (70.5%) were alive at the
end of the study. All patients were followed-up using proto-
col from Shanghai Municipal Center for Disease Control and
Prevention. The median follow-up time of all patients was
64.17 months (range 2.37–118.63 months).
According to the sixth edition of TNM staging system
criteria, there were 43 pT1N0M0 cases and 282 pT2N0M0
cases, 46 patients received adjuvant chemotherapy. The other
baseline characteristics of the patients are shown in Table 1,
including Eastern Cooperative Oncology Group performance
status, gender, smoking status, lobe location, VPI, and lym-
phovascular invasion (LVI).
Among the patients with stage IB NSCLC, 124 patients
were classified by tumor size 3 cm but with VPI, 32 patients
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were classified as tumor size3 cm alone. One hundred twenty-
six patients were classified by both tumor size 3 cm and
with VPI. Among these 126 patients, 16 patients were clas-
sified as hilar atelectasis or obstructive pneumonitis involving
less than the entire lung. Six patients with tumor involving
the mainstem bronchus 2 cm from the carina received
pneumonectomy. But all these 22 patients were classified by
tumor size 3 cm.
In our study, 68 patients were assigned to receive
mediastinal lymphadenectomy and 257 to receive mediastinal
lymph node sampling. The mean (SD) number of removed
lymph nodes was 7  4.6 (range 5–12). In the systematic
mediastinal lymphadenectomy group (n  68), the mean
(SD) removed lymph nodes number was 9  5.2 (range
7–12). In the mediastinal lymph node sampling group (n 257),
the mean (SD) removed lymph nodes number was 6  3.9
(range 5–10).
Adenocarcinoma was the most common type (n  179,
55.1%). Three patients were “pure” BAC, which were charac-
terized by a bronchioloalveolar lepidic growth pattern and no
evidence of stromal, vascular, or pleural invasion. Twenty-five
patients were adenocarcinoma with features of BAC. All slides
were checked by two pathology doctors.
Overall Survival
The median survival of the entire group of patients was
not reached with the median follow-up time of 64.17 months,
and the 5-year survival rate was 66.88%. Tumor size, gender,
age, lack of lymphvascular invasion, type of surgical resec-
tion, and type of lymph node resection were statistically
significant for OS on univariate analyses (Table 2). In all
pathologically staged I cases, there is significant OS differ-
ence between different tumor diameter (p 0.025, Figure 1).
When pT1N0M0 was divided into pT2 cm (n 28) and pT
2 to 3 cm (n 15), the respective 5-year survival rates were
not significantly different between the smallest two size
groups (78.57 and 73.33%, p  0.6488). When pT2NOM0
was divided into pT 2 cm (n  40), pT 2 cm but 3 cm
(n 84), pT3 to 5 cm (n 107), pT3 to 5 cm (n 38),
and pT 7 cm (n  13), the respective 5-year survival rate
were 72.98, 74.68, 60.87, 55.63, and 46.15%, respectively,
(p  0.0310) (Table 2).
The 5-year survival rate for patients with systematic
mediastinal lymphadenectomy (n  68) was 83.76%,
whereas patients with mediastinal lymph node sampling (n
257) was 66.44% (p  0.0239). Female patients (n  116)
was associated with an improved survival than men’s (n 
209; 75.67% versus 66.56%, p  0.032). Patients without
LVI (n  309) was associated with a better survival than
patients with LVI (n  16; 70.95% versus 50%, p  0.021),
lobectomy (n  300) was associated with a better survival
than patients with pneumonectomy and bilobectomy (n  19
versus 6; 71.14% versus 61.58% versus 33.33%, p  0.021),
Younger patients was associated with a better survival than
elder patients (n  178 versus 147; 78.22% versus 59.68%,
p 0.0001). There is no difference in OS between stages TIb
and TIa, Smoker or nonsmoker, patients with or without
adjuvant chemotherapy, and patients with or without visceral
pleural invasion.
Age, tumor size, gender, type of resection (pneumonec-
tomy, lobectomy, and bilobectomy), tumor size (greatest dimen-
sion of tumor), type of lymph node resection (systematic medi-
astinal lymphadenectomy or mediastinal lymph node sampling),
and lymphovascular vessel were significant for OS on multivar-
iate analysis (Table 3).
In our report, 43.97% of the stage IB patients (124 of 282
patients) had tumors3 cm because they were staged solely by
VPI criteria. Our result shows that there is no survival difference
between patients with or without VPI in staged I NSCLC (Table 4).
TABLE 1. Patient Characteristics
Patient Characteristics Number (%)
ECOG performance status
0 293 (90.15)
1 32 (9.85)
Alive
Yes 229 (70.5)
No 96 (29.5)
Gender
Male 209 (64.3)
Female 116 (35.7)
Histology
Squamous cell carcinoma 96 (29.5)
Adenocarcinoma 176 (54.2)
Adenosquamous cell carcinoma 47 (14.5)
Large-cell carcinoma 3 (0.9)
Bronchioloalveolar carcinoma (BAC) 3 (0.9)
Smoking status
Nonsmoker 153 (47.1)
Smoker 172 (52.9)
TNM stage
T1 43 (13.23)
T2 282 (86.77)
Type of resection
Pneumonectomy 6 (1.85)
Lobectomy 300 (92.31)
Bilobectomy 19 (5.84)
Lymph node removal
Systematic mediastinal lymphadenectomy 68 (20.92)
Mediastinal lymph node sampling 257 (79.08)
Lymphovascular invasion
Lymphovascular invasion 16 (4.92)
Without lymphovascular invasion 309 (95.08)
Adjuvant chemotherapy
Yes 46 (14.15)
No 279 (85.85)
Visceral pleural involvement
Yes 242 (74.5)
No 83 (25.5)
Lobe location
Left upper lobe 89 (27.38)
Left lower lobe 51 (15.69)
Right upper lobe 100 (30.77)
Right middle lobe 28 (8.62)
Right lower lobe 57 (17.54)
ECOG, Eastern Cooperative Oncology Group; TNM, tumor, node, metastasis.
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Disease-Free Survival
In all pathologically staged I cases, there is significant
DFS between different tumor diameter (p 0.009, Figure 2 and
Table 2). There is no significant difference in DFS in pT1
cases divided by size into pT 2 cm (n  28) and pT 2
to 3 cm (n  15). When pT2N0M0 was divided into five
categories, the respective 5-year survival rates were also signifi-
cantly different between these groups (p  0.027, Table 2).
Also patients’ age was significantly associated with
DFS in univariate analysis: 64.04% versus 46.78% for those
TABLE 2. Univariate Analysis of Pathological Stage I Non-Small Cell Lung Cancer According to
Clinical Factors
Patient Characteristics 5-yr Survival Rate (%) p 5-yr DFS Rate (%) p
Gender
Male 66.56 0.032 55.41 0.4913
Female 75.67 57.76
Age (yr)
65 78.22 0.0001 64.04 0.0055
65 59.68 46.78
Histology
Squamous cell carcinoma 71.58 0.372 67.71 0.086
Adenocarcinoma 65.18 52.96
Adenosquamous cell carcinoma 62.38 46.72
Large-cell carcinoma 66.67 33.33
Bronchioloalveolar carcinoma (BAC) 100 66.67
Smoking status
Nonsmoker 68.48 0.3039 53.46 0.7181
Smoker 65.39 58.69
Type of resection
Pneumonectomy 33.33 0.021 33.33 0.2422
Lobectomy 71.14 56.59
Bilobectomy 61.58 57.89
Type of lymph node resection
Systematic mediastinal lymphadenectomy 83.76 0.0239 58.43 0.268
Mediastinal lymph node sampling 66.44 55.62
Lymphovascular invasion
Lymphovascular invasion 50 0.021 37.5 0.0617
Without lymphovascular invasion 70.95 57.22
Adjuvant chemotherapy
Yes 69.48 0.5941 52.17 0.721
No 66.42 55.97
Visceral pleural involvement
Yes 66.67 0.4827 62.63 0.5275
No 67.12 54.04
T1
2 cm (n  28) 78.57 0.6488 75 0.7776
2–3 cm (n  15) 73.33 73.33
T2
2 cm (n  40) 72.98 0.0310 62.5 0.027
2–3 cm (n  84) 74.68 65.48
3–5 cm (n  107) 60.87 53.14
5–7 cm (n  38) 55.63 52.63
7 cm (n  13) 46.15 30.77
T1  T2
2 cm (n  68) 75.49 0.025 67.65 0.009
2 to 3 cm (n  99) 74.58 66.67
3 to 5 cm (n  107) 60.87 53.14
5 to 7 cm (n  38) 55.63 52.63
7 cm (n  13) 46.15 30.77
DFS, disease-free survival.
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younger than 65 years when compared with older than 65
(p  0.0055, Table 2).
DISCUSSION
The Tumor Size and Visceral Pleural
Involvement
The IASLC Lung Cancer Staging Project results show
that T1 tumors can be divided into two subgroups on the basis
of the best cut points identified by the running log-rank
analysis. Therefore, T1 tumors can be subdivided into two
prognostic groups: those 2 cm or smaller (T1a) and those
larger than 2 cm but no larger than 3 cm (T1b). Results from
other series support this division. Padilla et al.10 in a study on
158 patients with pT1- or pT2-NSCLC 3 cm or smaller in
diameter found that those 2 cm or smaller had better survival,
and that size was a better indicator of prognosis than endo-
bronchial invasion and visceral pleura involvement. Mulligan
et al.11 also found that tumors 2 cm or smaller in diameter had
a different prognosis from that of larger tumors; they have
suggested that these tumors alone should constitute T1, and
that those larger than 2 cm but no larger than 4 cm, or T1 with
pleural invasion, should constitute T2. In a large Japanese
multicenter series of patients with T1 NSCLC, the same
subgroups as those found in the analysis of the IASLC
database were formed according to tumor size.12 But in our
study, we found that 5-year survival rate was not significantly
different between the smallest two size groups (78.57%
versus 73.33%; p  0.6488), although 5-year survival rate of
IA group is higher than that of IB group. The number of T1
patients was only 43 and it is too small to show survival
differences. We found a trend that smaller tumors provides
better prognosis than larger tumors in stage IA NSCLC. A
prospective observational study is needed.
The IASLC Lung Cancer Staging Project results also
show that T2 tumors can be divided into three subgroups of
different prognosis. Other authors13,14 have reported on the
prognostic significance of the 5-cm landmark and have sug-
gested that T2 tumors larger than 5 cm should be upgraded.
A multicenter study15 on clinical and pathologic size found
that the prognostic landmarks were 2, 4, and 7 cm, and
suggested that T2 tumors larger than 7 cm should be up-
graded to T3.
In our study, the pN0M0 was divided into pT 2 cm
(n  68), pT 2 cm but 3 cm (n  99), p 3 cm but 5
cm (n  107), pT 5 to 7 cm (n  38), and pT 7 cm (n 
13). Their 5-year survival rate were 75.49, 74.58, 60.87,
55.63, and 46.15% (p  0.025), survival showed similar
figures to those reported in many series. Their 5-year DFS
rate were 67.65, 66.67, 53.14, 52.63, and 30.77% (p 
0.009), the multivariate analysis has revealed that tumor size
is an independent factor associated with survival. From the
analysis of the T component in our report, we can conclude that
there is sufficient validated information to consider the following
recommendations for changes in the seventh edition of the TNM
classification of lung cancer. The validity of classifying tumor
size by a cutoff point of 3 cm should be confirmed.
Tumor size has been a classic factor in determining
survival in patients with NSCLC, but the prognostic signifi-
cance of nonsize-based T descriptors such as VPI is less well
known. With the next revision to the TNM staging system for
NSCLC scheduled to be released in 2009, proposed revisions
to the T descriptor in early-stage NSCLC have been primarily
based on a subdivision of tumor size. However, the IASLC
Lung Cancer Staging Project results have not addressed in
detail how to reclassify the nonsize-based T2 criteria. A recent
study16 analyzed 10,545 stage IB NSCLC patients categorized
into the following three nonoverlapping criteria: (1) tumor size
(T2S); (2) visceral pleura invasion, hilar atelectasis, or obstruc-
tive pneumonitis (T2P); (3) main bronchus involvement2 cm
from the carina (T2C). The results showed T2P of 3 cm was
a poor prognostic factor for survival, T2P 3 cm was a favor-
able prognostic factor for survival. Our result shows that there is
FIGURE 1. The Kaplan-Meier survival stratified
by tumor diameter (T1  T2) (p  0.025).
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no survival difference between patients with or without VPI in
stage I NSCLC (Table 4). The invasion of visceral pleural failed
to provide more prognostic information than tumor size alone.
Type of Lymph Node Resection and Gender
In this study, we found significant difference in survival
between systematic mediastinal lymphadenectomy and me-
diastinal lymph node sampling in patients with pathologic
stage I NSCLC. The 5-year survival rate for patients with
systematic mediastinal lymphadenectomy was 83.76%,
whereas patients with mediastinal lymph node sampling was
66.44% (p  0.0239). Many investigators have emphasized
the importance of systematic mediastinal lymphadenectomy
for patients with resectable NSCLC, because its staging
accuracy can contribute to patient selection for adjuvant
therapy and prediction of prognosis.17–23 However, the ben-
efit of systematic mediastinal lymphadenectomy for the pa-
tients with clinical stage I NSCLC is still controversial.17,18,24
Sugi et al.24 reported that there was no significant difference
in recurrence rate or survival in patients with NSCLC smaller
than 2 cm in diameter between systematic mediastinal lymph-
adenectomy and mediastinal lymph node sampling. Unfortu-
nately, there was no consensus to define the extent of surgery
and numbers of lymph nodes that should be dissected. More
prospective data are required to set the threshold number of
lymph nodes dissected for quality evaluation.
Previous studies that have addressed the effect of gen-
der on the outcome of lung cancer have suggested that female
gender carries some survival advantage. This study confirms
that women had statistically better outcomes than that of men.
Several studies have reported gender-specific differences in
survival in surgically treated patients with NSCLC, with
women uniformly having better outcomes.25–28 The reasons
for this survival advantage have not been identified but most
likely due to a variety of factors. In our study, surgery was
performed more frequently in men than in women with
local-stage disease. Although this may have been due to a
somewhat older age distribution and possibly to more severe
comorbidity in men, the exact reasons for this gender-specific
difference in treatment are not discernible from our data.
Because surgery offers patients with local-stage disease the
best chance for long-term survival, this difference in treat-
ment may partially explain the significantly superior survival
noted for women with local-stage disease.
There are other possible factors contributed to a higher
female survival rate. It was reported that the only statistically
significant relationship could be found between survival rate
TABLE 3. Multivariate Cox Proportional Hazards Model
Analyses of Various Factors Affecting Overall Survival (OS)
Multivariate HR (95% CI) p
Agea (yr)
65 Reference group 0.001
65 2.162 (1.396–3.346)
Gender
Male Reference group 0.017
Female 2.077 (1.142–3.778)
Histology
Squamous cell Reference group 0.140
Adenocarcinoma 0.439 (0.053–3.664)
Squamous and adenocarcinoma 0.292 (0.035–2.420)
Large-cell carcinoma 1.550 (0.128–18.702)
Bronchioloalveolar carcinoma (BAC) 3.586 (0.932–19.420)
Smoking status
Nonsmoker Reference group 0.227
Smoker 1.560 (0.882–2.759)
Lymph node
Systematic mediastinal
lymphadenectomy
Reference group 0.014
Mediastinal lymph node sampling 2.248 (1.177–4.293)
Adjuvant chemotherapy
Yes Reference group 0.559
No 1.212 (0.636–2.311)
Lymphovascular invasion
Without lymphovascular invasion Reference group 0.014
Lymphovascular invasion 2.248 (1.177–4.293)
Visceral pleural involvement
Yes Reference group 0.613
No 0.861 (0.483–1.586)
Type of resection
Pneumonectomy Reference group 0.01
Lobectomy 0.336 (0.086–0.920)
Bilobectomy 0.427 (0.125–1.359)
T
2 cm Reference group 0.027
2 to 3 cm 0.999 (0.491–2.034)
3 to 5 cm 1.520 (0.734–3.149)
5 to 7 cm 2.315 (0.979–5.475)
7 cm 3.808 (1.358–10.675)
T category
T2 Reference group 0.555
T1 0.755 (0.297–1.921)
a Median age.
HR, hazard ratio; CI, confidence interval.
TABLE 4. Comparisons of Overall Survival Between Visceral
Pleural Involvements or Not
T Category Number
Visceral Pleural
Involvements
5-yr Survival
Rate (%) p
3 cm
(n  167)
(T2) 124 Yes 74.14 0.7332
(T1) 43 No 76.74
pT 3–5 cm
(n  107)
(T2) 83 Yes 69.72 0.1468
(T2) 24 No 54.01
pT 5–7 cm
(n  38)
(T2) 30 Yes 61.76 0.4134
(T2) 8 No 48.61
pT 7 cm
(n  13)
(T2) 13 All with
involvement
46.15 NS
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and female gender plus a lower level of lymph node spreads
according to a Cox analysis post surgery.29 Exogenous or
endogenous estrogens,30 gene, emotional factors may also
play important roles in the development and survival of the
lung cancer for women.31
Lymphovascular Invasion, Age, and Type
of Resection
LVI has long been associated with poor survival and
aggressive tumor behavior. In a recent review32 about gastric
cancer, LVI emerged as a prognostically promising factor,
which independently predicted survival and was associated
with advanced T stage, prompting some authors to suggest
that LVI should be included in risk stratification and selection
of patients for entry into clinical trials. Our results indicated
that LVI was predictive of survival in node-negative patients,
and were in agreement with previous studies examining
node-negative gastric cancer, further supporting LVI as a
potential marker of biologic behavior. To better understand
the role of LVI in lung cancer, further study is necessary.
Elderly cancer patients often present with medical and
physiologic challenges that make the selection of their opti-
mal treatment daunting. Aging is inextricably associated with
physiologic changes in functional status, organ function, and
drug pharmacokinetics. Furthermore, concomitant comor-
bidities that affect functional status, general health, and tumor
symptoms are frequently present in this patient group. Al-
though studies have shown that elderly patients with good
lung and heart function and a good performance status can
tolerate lung cancer surgery as well as younger patients with
a similar chance for cure.33,34
Christos Alexiou et al.35 reported 485 patients with
stage I NSCLC undergoing lung resection between 1991 and
2000. Three hundred seventy-four patients underwent a smaller
resection than a pneumonectomy and 111 had a pneumonec-
tomy. Overall 1-, 3-, and 5-year Kaplan-Meier survival rates
(95% CI) after less extensive resections were 85 (CI, 82–
90%), 63 (CI, 56–69%), and 50% (CI, 42–57%), respec-
tively, and after pneumonectomy, the survival rates were 66
(CI, 53–73%), 47 (CI, 35–57%), and 44% (CI, 32–55%),
respectively (p  0.0006). In our study, the patients who
underwent pneumonectomy for stage pT1N0 or pT2N0 had a
significantly poorer survival than those patients who under-
went smaller lung resections.
SUMMARY
In conclusion, we are well aware of that this is a
retrospective study, of course, our results do not have the
same strength as a observational study, and however, it
provides a substantial basis for the design of future random-
ized, prospective clinical trials and treatment strategies. We
get the similar results that are in concordance with the IASLC
Lung Cancer Staging Project recommends in the T classifi-
cation, although we found no statistical differences between
patients with tumors with 2 cm or less in size and those with
tumors from 2 to 3 cm. This new system will greatly improve
the usefulness of TNM lung staging across all of its purposes.
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